Sergei Petukhov

Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA.

Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA.

Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA.

Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA.

Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA.